CaMKK2 intensity increased with tumor progression in a transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model of PCa, and its expression was higher in castration-resistant tumor xenografts than androgen-responsive ones. The gene discussed is CAMKK2; the disease is neoplasm.